LINC00330 and esophageal squamous cell carcinoma: This finding suggested that LINC00330 can suppress the progression of ESCC by inhibiting the expression of CCL2, thereby blocking the activation of the CCL2/CCR2 axis and its downstream signal transduction pathways, promoting TAM reprogramming, and inhibiting ESCC progression.